Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Just Reported Increased Shorts

May 16, 2018 - By Winifred Garcia

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) registered an increase of 2.99% in short interest. ARWR’s total short interest was 6.79M shares in May as published by FINRA. Its up 2.99% from 6.60 million shares, reported previously. With 736,000 shares average volume, it will take short sellers 9 days to cover their ARWR’s short positions. The short interest to Arrowhead Pharmaceuticals Inc’s float is 9.95%.

The stock decreased 0.94% or $0.09 during the last trading session, reaching $9.51. About 1.16M shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 265.61% since May 16, 2017 and is uptrending. It has outperformed by 254.06% the S&P500.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $832.86 million. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 7 analysts covering Arrowhead Research (NASDAQ:ARWR), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Arrowhead Research had 12 analyst reports since November 27, 2017 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, February 12 by Cantor Fitzgerald. The rating was maintained by FBR Capital with “Hold” on Tuesday, March 27. On Wednesday, May 9 the stock rating was upgraded by Cantor Fitzgerald to “Overweight”. FBR Capital maintained the stock with “Hold” rating in Monday, February 12 report. B. Riley & Co maintained it with “Neutral” rating and $4 target in Monday, February 12 report. PiperJaffray upgraded Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Monday, November 27 to “Overweight” rating. The rating was maintained by FBR Capital on Monday, March 12 with “Hold”. On Monday, November 27 the stock rating was upgraded by Piper Jaffray to “Buy”.

Another recent and important Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news was published by which published an article titled: “2 Upgraded Drug Stocks Squeezing Shorts” on May 09, 2018.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.